HANGZHOU, China, Aug. 26, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK), a leading player in China's peripheral and neurovascular intervention markets, today announced its interim financial results for 2024. The Company reported revenue of $51.26 million, a 59.0% increase year-over-year, and achieved a net profit of $9.66 million, marking its first profitable half-year. This milestone highlights the Company's ability to navigate a dynamic market landscape, achieving scale and entering a new phase of sustainable growth.
In the first half of 2024, Zylox-Tonbridge launched several pioneering products in China, addressing unmet clinical needs and expanding treatment options for physicians and patients. By leveraging Volume-based Procurement (VBP) initiatives, the Company significantly increased market penetration with its comprehensive and high-quality product portfolio. As of June 2024, Zylox-Tonbridge has received marketing approvals for 44 products from the National Medical Products Administration (NMPA). Notably, revenue from neurovascular and peripheral vascular interventions increased by 46.7% to approximately $34.2 million and by 88.2% to roughly $16.9 million, respectively.
During this period, Zylox-Tonbridge expanded its international presence, with products now available in 22 countries, including Germany, France, ...
